Clinical Features

Clinical Presentation of PDThe characteristic symptoms of PD are tremor, bradykinesia, rigidity and postural instabilityClinical Presentation of PDThe characteristic symptoms of PD are tremor, bradykinesia, rigidity and postural instabilityParkinson's disease presents with a range of motor, cognitive, psychiatric, sensory, and autonomic symptoms.

Some of the physical challenges PD patients face are symptoms inherent to the disease, while others are treatment-related side effects. Some of the most onerous phenomena seen in PD patients, such as dyskinesia, are side effects of drug therapies that aim at reducing the effects of the dopamine depletion that occurs as a result of PD pathology.

The initial diagnosis of PD is based on medical history and a neurological examination using clinical scales to test for the presence of characteristic motor symptoms: tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms of PD (cognitive, psychiatric, autonomic, sensory and sleep disorders) present with considerable variability, and there is evidence that some (such as anosmia) can predate the occurrence of motor symptoms.

Symptoms of PD can also be categorized by whether or not they are responsive to dopamine replacement therapies. So-called ‘dopamine non-responsive symptoms’ include gait disorders and various non-motor symptoms.

10 Jun 2009 10:12 PM EST
Today's morning sessions, Lessons on the basal ganglia from neighboring disciplines chaired by Etienne Hirsch and Joseph Jankovic, and Complexity of genetics in hyperkinesias chaired by Timothy Lynch ... 
9 Oct 2009 02:39 PM EST
Some discussion at a recent MJFF Awardee meeting focused on the nonmotor symptoms of Parkinson’s disease, with input from both basic scientists and clinicians. Presentations addressed a novel ... 
10 Mar 2010
There is still an on-going debate concerning whether Parkinson disease with dementia (PDD) and dementia with Lewy bodies  (DLB) are distinct entities. Clinically, both conditions can be ... 
14 Jan 2010
The authors describe a dopamine agonist withdrawal syndrome (DAWS) in the context of a retrospective cohort study.  The withdrawal syndrome occurred in 5 subjects among 26 who ... 
04 Jan 2010
Non motor effects of pedunculopontine nucleus stimulation ... 
12 Mar 2010
Is PD-associated fatigue truly a distinctly different symptom from PD-associated sleep disturbance?  If so, is this thought to be due to separate anatomic substrates or biological factors ... 
29 Oct 2009
PD therapeutics development presents many trial design challenges, such as, for example, the difficulty of measuring changes in disease progression, and the inherent variability in clinical ... 
Responses: 2
15 Jul 2009
There is some evidence that different forms of Parkinson's disease exist and that the severity of disease course may be linked to these possible subtypes. To date, there is little understanding of ... 
Responses: 7
30 Jun 2009
This Funding Opportunity Announcement (FOA), issued by the National Institute of Mental Health (NIMH) with participation from the National Institute on Aging (NIA), the National Institute on Alcohol ... 
30 Jun 2009
The objective of the Alzheimer’s Disease Pilot Clinical Trials initiative is to improve the quality of clinical research designed to evaluate interventions for the prevention and treatment of ... 
11 Jun 2009
Brief Description:The National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other ... 
24 Mar 2009
Barcelona, Spain Contact: KENES International, 1-3 rue de Chantepoulet, P.O. Box 1726, CH-1211 Geneva 1, Switzerland; TEL: +41-22-908-0488; FAX: +41-22-732-2850; E-mail: vascular@kenes.com Web site: www.kenes.com/vascular ... 
24 Mar 2009
AVilla Mondragone, Rome, Italy Contact: Antonio Pisani, MD, University of Rome Tor Vergata, Rome, Italy; TEL: +39-0672596010; FAX: +39-0672596006; E-mail: pisani@uniroma2.it Web site: dystonia.uniroma2.it/   ... 
A recent report in the Archives of Neurology investigates dopamine agonist withdrawl in Parkinson's patients. The authors show a subset of patients (19% - 5 of the 26 who underwent DA taper) ... 
14 Jan 2010
Responses: 1
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this ... 
27 Aug 2009
Responses: 1
BOULDER, Colo., Aug. 18 /PRNewswire-USNewswire/ -- The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced ... 
18 Aug 2009
23 Feb 2010
DBS is a technique which is using for treating movement disorders such as Parkinson and dystonia. This technique gives an opportunity to record local field potential through DBS electrodes from ... 
02 Dec 2008
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time ... 
04 Oct 2008
There's high incidence of seborrhic dermatitis among patients suffering from Parkinson's disease. Seborrhic dermatitis is caused by increased exertion of sebaceous glands. Previous ... 
18 Mar 2008
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on end-of-dose wearing off in persons who ...